Conditions: Healthy Subjects
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 34
Healthy volunteers: yes

Brief summary:
The primary objective of this study was to assess the effects of subcutaneous sumatriptan alone and the effects of a single dose of erenumab (AMG 334) intravenous (IV) and sumatriptan concomitant therapy on resting blood pressure in healthy adults.

Detailed description:

Arms:
arm 1: Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received another placebo IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2). arm 2: Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received 140 mg erenumab IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).

Interventions: intervention 1: Placebo intervention 2: Sumatriptan intervention 3: Erenumab
Intervention descriptions: intervention 1: Administered by intravenous infusion intervention 2: Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5 intervention 3: Administered by intravenous infusion

Protocol document: